Coronavirus (COVID-19): does Ivermectin prevent transmission or aid in the treatment of COVID-19?
Vanessa Jordan
+ Author Affiliations
- Author Affiliations
New Zealand Cochrane Fellow, University of Auckland, Auckland, New Zealand. Email: v.jordan@auckland.ac.nz
Journal of Primary Health Care 13(3) 287-288 https://doi.org/10.1071/HC19563
Published: 30 September 2021
Journal Compilation © Royal New Zealand College of General Practitioners 2021 This is an open access article licensed under a Creative Commons Attribution 4.0 International License
References
[1] Popp M, Stegemann M, Metzendorf M-I, et al. Ivermectin for preventing and treating COVID‐19. Cochrane Database Syst Rev. 2021; CD015017| Ivermectin for preventing and treating COVID‐19.Crossref | GoogleScholarGoogle Scholar | 34318930PubMed |
[2] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19, 11 March 2020. 2020.
[3] Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad, Ser B, Phys Biol Sci. 2011; 87 13–28.
| Ivermectin, ‘wonder drug’ from Japan: the human use perspective.Crossref | GoogleScholarGoogle Scholar |
[4] Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178 104787
| The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.Crossref | GoogleScholarGoogle Scholar | 32251768PubMed |
[5] Wehbe Z, Wehbe M, Iratne R, et al. Repurposing Ivermectin for COVID-19: molecular aspects and therapeutic possibilities. Front Immunol. 2021; 12 663586
| Repurposing Ivermectin for COVID-19: molecular aspects and therapeutic possibilities.Crossref | GoogleScholarGoogle Scholar | 33859652PubMed |
